Organisation paid for research Program year 2024 Source: CMS Open Payments

Bryant Research Group

Neither a doctor nor a teaching hospital

Research payments

$293,514

178 payments

Through program year 2024, Bryant Research Group is reported as receiving $293,514 in research payments, across 178 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $84,626 16
2023 Research $144,081 43
2022 Research $55,600 80
2021 Research $5,646 38
2020 Research $3,561 1

Breakdown

Who paid Research payments · program years 2020–2024
  1. AbbVie, Inc. $245,783 47 payments
  2. Novartis Pharmaceuticals Corporation $30,013 1 payment
  3. Teva Pharmaceuticals USA, Inc. $17,719 130 payments
Studies the money was for Research payments · program years 2020–2024
  1. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $116,085 24 payments
  2. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $82,026 17 payments
  3. A 12 Months Prospective, Interventional, Multinational, Open-Label, Active-Controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab 140 MG QM VS Oral Prophylactics) $30,013 1 payment
  4. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $24,115 2 payments
  5. A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice $14,158 129 payments
  6. Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. $13,850 2 payments
  7. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $8,161 1 payment
  8. A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH) $3,561 1 payment
  9. M22-418 Atogepant-Botox Combination Study $1,545 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record